Determination 2
Determination 2 - Isatuximab, Iberdomide, Bortezomib and Dexamethasone Induction, Followed by Risk- and Response-Adapted Consolidation and Maintenance Therapy, in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma
More Information
- Trial Status
- Not yet accepting
- Trial Phase
- Phase 3
- Enrollment
- 720 patients (estimated)
- Tags
- Monoclonal Antibody, CD38, Maintenance, Randomization
- Trial Type
- Treatment
- Last Update
- SparkCures ID
- 2263
- NCT Identifier
- NCT07624513
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.